Development of non-viral vehicles for targeted gene transfer into microglia via the integrin receptor CD11b

Inflammatory microenvironment-targeted nanotherapies

Inflammatory microenvironments (IMEs) are common pathological characteristics and drive the development of multiple chronic diseases. Thus, IME-targeted therapies exhibit potential for the treatment of inflammatory diseases. Nanoplatforms have significant advantages in improving the efficiency of anti-inflammatory treatments. Owing to their improved therapeutic effects and reduced side effects, IME-targeted nanotherapies have recently drawn interest from the research community. This review introduces IMEs and discusses the application of IME-targeted nanotherapies for inflammatory diseases. The development of rational targeting strategies tailored to IMEs in damaged tissues can help promote therapies for chronic diseases.

Proliferation of NG2 cells in the epileptic hippocampus

NG2 cells are oligodendrocyte progenitor cells, and have been shown to receive synaptic input from pyramidal neurons to generate action potentials. Whether any change of these cells occurs after status epilepticus (SE) and subsequent temporal lobe epilepsy remains unknown. In the present study, the expression of NG2 was investigated in the mouse hippocampus after pilocarpine-induced status epilepticus (PISE). We showed that reactive NG2 cells were significantly increased from 1 day to 2 months after PISE. Double immunofluorescence indicated that few NG2 cells differentiated into neurons and astrocytes after PISE, whereas the number of NG2 cells was increased significantly in the stratum lucidum of CA3 area from 1 day onwards after PISE. Our results suggest that the significantly increased reactive NG2 cells from acute to chronic stage after PISE may be involved in epileptogenesis.

Brain-Targeted Polymers for Gene Delivery in the Treatment of Brain Diseases

Gene therapies have become a promising strategy for treating neurological disorders, such as brain cancer and neurodegenerative diseases, with the help of molecular biology interpreting the underlying pathological mechanisms. Successful cellular manipulation against these diseases requires efficient delivery of nucleic acids into brain and further into specific neurons or cancer cells. Compared with viral vectors, non-viral polymeric carriers provide a safer and more flexible way of gene delivery, although suffering from significantly lower transfection efficiency. Researchers have been devoted to solving this defect, which is attributed to the multiple barriers existing for gene therapeutics in vivo, such as systemic degradation, blood-brain barrier, and endosome trapping. This review will be mainly focused on systemically administrated brain-targeted polymers developed so far, including PEI, dendrimers, and synthetic polymers with various functions. We will discuss in detail how they are designed to overcome these barriers and how they efficiently deliver therapeutic nucleic acids into targeted cells.